Glaxo says settles some Paxil birth-defect cases

* Settles certain cases involving Paxil use during pregnacy

* No comment on report of $1 billion settlement deal

LONDON, July 20 (BestGrowthStock) – GlaxoSmithKline (GSK.L: ) said on
Tuesday it had agreed to settle certain U.S. lawsuits alleging
its Paxil antidepressant caused birth defects in some patients
but declined to put a figure on the settlements.

“GSK has reached agreement to settle certain cases involving
the use of Paxil during pregnancy. The details of those
settlements are confidential,” spokeswoman Claire Brough said in
an e-mailed statement.

“Other cases remain pending. Three cases are scheduled for
trial in Philadelphia in September,” she added.

“GSK considers options for every case, including settlement
when it makes sense. The company has agreed to these
settlements, despite its litigation defences, in order to avoid
the costs, burdens and uncertainties of ongoing litigation.”

Bloomberg News, citing people familiar with the settlements,
earlier said the drugmaker had agreed to pay more than $1
billion to resolve more than 800 birth-defect cases related to
Paxil.

News of the Paxil settlements comes after British-based
Glaxo said last week it was taking a 1.57 billion-pound ($2.4
billion) legal charge to cover litigation related to Paxil, as
well as to its diabetes pill Avandia and a former factory in
Puerto Rico.

In the case of Paxil, the company said on July 15 that it
had settled the “vast majority” of product liability cases.

Glaxo is due to report second-quarter financial results at
1100 GMT on Wednesday,

Investing Advice

($1=.6583 pounds)
(Reporting by Ben Hirschler; Editing by Greg Mahlich)

Glaxo says settles some Paxil birth-defect cases